1202357-66-1

Basic information

• Product Name: 2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester
• Synonyms: 2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester;ethyl 2-[(6-chloro-2-methylpyrimidin-4-yl)amino]-1,3-thiazole-5-carboxylate
• CAS NO: 1202357-66-1
• Molecular Formula: C₁₁H₁₁ClN₄O₂S
• Molecular Weight: 298.75
• Mol File: 1202357-66-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester(1202357-66-1)
• EPA Substance Registry System: 2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester(1202357-66-1)

Safety Data

• Hazardous Substances Data: 1202357-66-1(Hazardous Substances Data)

Usage

Chemical structure

2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester consists of a thiazole ring and a pyrimidine ring, with a carboxylic acid and ethyl ester groups attached.

Potential applications

The compound has potential pharmaceutical applications, particularly in the development of new drugs for antiviral and antibacterial purposes.

Biological activity

The presence of chloro and methyl substituents on the pyrimidine ring may contribute to the compound's biological activity, affecting its interaction with biological systems.

Medicinal chemistry research

The compound is likely to be used in medicinal chemistry research to study its biological and pharmacological properties, which may lead to the development of effective drugs.

Further studies

Additional research may be needed to fully understand the properties and potential applications of 2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester in the context of drug development.

Upstream product

• 1780-26-3 2,4-dichloro-2-methylpyrimidine 
• 32955-21-8 2-amino-thiazole-5-carboxylic acid ethyl ester 

Downstream Products

• 1497436-07-3 (2E)-N-(2-chloro-6-methylphenyl)-2-[(6-chloro-2-methylpyrimidin-4-yl)imino]-3-(4-methoxybenzyl)-2,3-dihydro-1,3-thiazole-5-carboxamide 
• 1497436-11-9 (2E)-N-(2-chloro-6-methylphenyl)-3-(4-methoxybenzyl)-2-[(2-methyl-6-piperazin-1-ylpyrimidin-4-yl)imino]-2,3-dihydro-1,3-thiazole-5-carboxamide 
• 1497436-15-3 C₃₀H₃₀⁽²⁾H₄ClN₇O₃S 
• 1497436-18-6 C₄₁H₄₉⁽²⁾H₄ClN₈O₆S 
• 1497436-02-8 (2E)-2-[(6-chloro-2-methylpyrimidin-4-yl)imino]-3-(4-methoxybenzyl)-2,3-dihydro-1,3-thiazole-5-carboxylic acid 
• 1497435-99-0 ethyl (2E)-2-[(6-chloro-2-methylpyrimidin-4-yl)imino]-3-(4-methoxybenzyl)-2,3-dihydro-1,3-thiazole-5-carboxylate 
• 903564-48-7 2-{6-[4-(2-hydroxyethyl)-piperazin-1-yl]-2-methylpyrimidin-4-ylamino}-thiazole-5-carboxylic acid [2-methyl-5-(3-trifluoromethylbenzoylamino)-phenyl]-amide 
• 302964-08-5 2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide 
• 302962-49-8 dasatanib 

Relevant articles and documents

HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention are distinctive; possessing a particular class of halogenated heteroaryls. Such kinase inhibitors can display one or more certain properties distinct to dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally similar kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions disclosed herein may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF

The invention is based on the surprising finding that SIK3 is associated with resistance against anti-tumour immune responses. In particular, the invention provides methods for treating proliferative diseases using inhibitors of SIK3, especially nucleic acid or small molecule inhibitors of SIK3. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of certain pro-inflammatory signalling pathways, and/or to kill such cells and/or methods for treating proliferative diseases, using a SIK3 inhibitor together with ligands or agonists of such signalling pathways. Other methods provided by the invention include those involving SIK3 inhibitors to enhance or overcome certain side effects associated with treatments that utilise such signalling pathways, as well as diagnostic, prognostic and monitoring methods and kits based on the detection of SIK3 in a sample obtained from a subject, and screening methods useful for identifying or characterising inhibitors of SIK3.

DUAL SRC/P38 KINASE INHIBITOR COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

Dual Src/p38 kinase inhibitor compounds and compositions comprising the same are disclosed. Methods of using the compounds in the treatment of hyperproliferative disease such as cancer are also disclosed.